Trump Should End the FDA’s 25-Year Cover-Up on the Abortion Pill
National Review
by Tim Chapman and Marc WheatFebruary 14, 2026
AI-Generated Deep Dive Summary
Trump calls for an end to the FDA’s 25-year alleged concealment of the abortion pill mifepristone. Critics argue that while the drug's safety hasn't improved, political influences have grown stronger within the agency.
Mifepristone has been a contentious issue since its introduction, with debates over its safety and efficacy dominating public discourse. The FDA’s handling of the drug has faced scrutiny, particularly regarding transparency and regulatory decisions influenced by political agendas. Trump has long criticized the FDA for what he perceives as overreach and partisanship.
The abortion pill’s approval process and ongoing oversight have sparked concerns among both supporters and opponents of reproductive rights. Advocates argue that mifepristone provides a safe and effective option for early-term abortions, while others raise questions about its risks and long-term health effects. The FDA’s role in managing these issues has come under increasing pressure as political divisions widen.
Recent allegations suggest that the FDA has prioritized political considerations over scientific evidence when it comes to mifepristone. Critics claim that this dynamic undermines public trust in regulatory agencies and sets a dangerous precedent for future policy decisions.
For readers interested in politics, understanding the interplay between science and politics in regulatory bodies like the FDA is crucial. The debate over mifepristone highlights broader concerns about transparency, accountability, and the potential for political influence in public health policies.
Verticals
politicsconservative
Originally published on National Review on 2/14/2026